MCRB

Seres Therapeutics Inc

Add to Watchlist

Advanced Chart

19.640

-0.45(-2.240%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

20.2471

Open

20.000

VWAP

19.72

Vol

73.06K

Mkt Cap

171.94M

Low

19.300

Amount

1.44M

EV/EBITDA(TTM)

Total Shares

151.45M

130.50M

EV/OCF(TTM)

P/S(TTM)

Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

0.425

-96.34%

-2.265

+2.95%

-2.710

-172.27%

Estimates Revision

The market is revising No Change the revenue expectations for Seres Therapeutics, Inc. (MCRB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 69.31%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-5.5%

In Past 3 Month

Stock Price

Go Up

+69.31%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast MCRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCRB is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 19.640

Low

22.00

Averages

22.00

High

22.00

Current: 19.640

Low

22.00

Averages

22.00

High

22.00

Canaccord

Buy

maintain

$14 -> $22

2025-09-24

Reason

Canaccord

Price Target

$14 -> $22

2025-09-24

maintain

Buy

Reason

Canaccord raised the firm's price target on Seres Therapeutics to $22 from $14 and keeps a Buy rating on the shares. The firm noted the FDA provided feedback on Seres' proposed Phase 2 SER-155 study in bloodstream infections, which could aid in partnership discussions while also noting Seres is reducing staff by 25%, including August 2025 reductions, which should provide sufficient cash to fund operations into 2Q26.

Chardan

Buy -> Neutral

downgrade

2025-05-08

Reason

Chardan

Price Target

2025-05-08

downgrade

Buy -> Neutral

Reason

Chardan downgraded Seres Therapeutics to Neutral from Buy with a $6 price target.

Chardan Capital

Keay Nakae

Strong Buy

Maintains

$1.25

2025-03-20

Reason

Chardan Capital

Keay Nakae

Price Target

$1.25

2025-03-20

Maintains

Strong Buy

Reason

Goldman Sachs

Chris Shibutani

Strong Sell

Maintains

$1 → $0.75

2025-03-14

Reason

Goldman Sachs

Chris Shibutani

Price Target

$1 → $0.75

2025-03-14

Maintains

Strong Sell

Reason

Canaccord Genuity

John Newman

Strong Buy

Maintains

$10

2024-11-14

Reason

Canaccord Genuity

John Newman

Price Target

$10

2024-11-14

Maintains

Strong Buy

Reason

Chardan Capital

Keay Nakae

Strong Buy

Maintains

$1.25

2024-11-13

Reason

Chardan Capital

Keay Nakae

Price Target

$1.25

2024-11-13

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Seres Therapeutics Inc (MCRB.O) is -2.65, compared to its 5-year average forward P/E of -6.56. For a more detailed relative valuation and DCF analysis to assess Seres Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.56

Current PE

-2.65

Overvalued PE

8.55

Undervalued PE

-21.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.69

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

12.62

Undervalued EV/EBITDA

-26.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

24.49

Current PS

0.00

Overvalued PS

52.02

Undervalued PS

-3.03